Scleroderma
Conditions
Brief summary
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.
Interventions
PROCEDURESkin samples
* Scleroderma group: skin biopsy for scleroderma patients * Control group: recovery of resected tissue from patients undergoing plastic, reconstructive and aesthetic surgery.
OTHERAnalysis of fibroblasts
Analysis of samples by RNA sequencing
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
FOR PATIENTS WITH SCLERODERMA : * Person who has given written consent * Person with systemic scleroderma FOR CONTROL PARTICIPANTS : * Person who has given written consent * Person undergoing plastic, cosmetic and reconstructive surgery
Exclusion criteria
FOR PATIENTS WITH SCLERODERMA : * Person not affiliated to or not benefiting from a social security scheme * Person subject to a legal protection measure (curatorship, guardianship) * Person subject to a legal protection measure * An adult who is incapable or unable to give consent * Minors FOR CONTROLLED PARTICIPANTS : * Person suffering from a chronic disease or under chronic treatment for autoimmune, inflammatory or dermatological diseases * Person not affiliated to or not benefiting from a social security scheme * Person under legal protection (curatorship, guardianship) * Person subject to a legal protection measure * An adult who is incapable or unable to give consent * Minors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| genes involved in the various cell activation and signalling pathways | through study completion, an average of 12 months | number and type of genes involved in different cell activation and signalling pathways, including senescence, which will be differentially expressed in fibroblasts from the skin of control participants and those from the skin of subjects with SSc. |
Countries
France
Contacts
CONTACTBernard BONNOTTE
Outcome results
None listed